Not available
Quote | United Therapeutics Corporation (NASDAQ:UTHR)
Last: | $237 |
---|---|
Change Percent: | 0.37% |
Open: | $233.61 |
Close: | $237 |
High: | $241 |
Low: | $233.275 |
Volume: | 574,086 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | United Therapeutics Corporation (NASDAQ:UTHR)
2024-04-24 10:23:46 ET More on United Therapeutics United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects United Therapeutics Corporation (UTHR) Q4 2023 Earnings Call Transcript United Therapeutics Corporation 2023 Q4 - Results ...
The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant This transplant builds on two successful UHeart transplants completed in 2022 and 2023 United Therapeutics Corporation (Nasdaq: UTHR ), a publi...
Message Board Posts | United Therapeutics Corporation (NASDAQ:UTHR)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $UTHR News Article - United Therapeutics Corporation Reports Third Quarter 2022 Financi | whytestocks | investorshangout | 11/02/2022 3:20:49 PM |
whytestocks: $UTHR News Article - United Therapeutics Announces First Patient Enrolled in Phase 3 TE | whytestocks | investorshangout | 10/11/2022 5:55:54 PM |
whytestocks: $UTHR News Article - Innovators in Pharma Sectors See Potential, Promise in Providing I | whytestocks | investorshangout | 08/05/2021 12:45:47 PM |
whytestocks: $UTHR News Article - United Therapeutics Corporation Reports Second Quarter 2021 Financ | whytestocks | investorshangout | 08/04/2021 2:45:49 PM |
whytestocks: $UTHR News Article - This Pharma Can Breathe New Life Into Your Portfolio | whytestocks | investorshangout | 04/02/2021 12:00:50 PM |
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant This transplant builds on two successful UHeart transplants completed in 2022 and 2023 United Therapeutics Corporation (Nasdaq: UTHR ), a publi...
United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. ...
Initial, interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open label study to be presented at a poster discussion session An annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fib...